Commissioner Olivér Várhelyi, in a written answer on 9 July 2026, told the European Parliament that the Commission does not consider the hantavirus outbreak a medical emergency and has no plans to authorise an mRNA vaccine via fast-track procedures. The answer, responding to a question from Austrian MEP Gerald Hauser (PfE), downplays the risk and stresses that any future vaccine would undergo standard rigorous assessment by the European Medicines Agency (EMA).
Várhelyi noted that the European Centre for Disease Prevention and Control (ECDC) assessed the risk as 'very low' and that the Health Security Committee (HSC) opinion of 12 May 2026 reflected this assessment. He stated there is 'no indication that Europe may face a public health emergency that might lead to further measures,' citing Council Regulation (EU) 2022/2372 on crisis-relevant medical countermeasures. The Commissioner also pointed to EMA's active monitoring of the cruise ship outbreak.
On vaccine authorisation, Várhelyi said development of hantavirus vaccines is 'still at an early stage' and that any application would be subject to 'rigorous assessment of its safety, efficacy and quality' before a decision is taken. This effectively rules out fast-track procedures similar to those used for COVID-19 vaccines.
The answer provides no concrete proposals, numerical targets, or deadlines. It is a declarative reassurance aimed at calming public concern and clarifying that no emergency measures are imminent. The Commission's stance aligns with WHO's assessment that human-to-human transmission is 'uncommon' and with the ECDC's low-risk classification.
Institutional follow-up is unlikely in the near term. The Commission will continue monitoring through the HSC and ECDC, but no legislative or regulatory action is signalled. The answer may face pushback from MEPs who view the situation more seriously, but for now the Commission maintains a wait-and-see approach.